Endometrial Cancer Clinical Trials in Seoul
21 recruitingSeoul, South Korea
Showing 1–20 of 21 trials
Recruiting
Phase 3
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Endometrial Cancer
BioNTech SE480 enrolled132 locationsNCT06340568
Recruiting
Phase 3
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Endometrial Cancer
Karyopharm Therapeutics Inc276 enrolled217 locationsNCT05611931
Recruiting
Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Endometrial Cancer
Merck Sharp & Dohme LLC1,123 enrolled245 locationsNCT06952504
Recruiting
Phase 3
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Endometrial CancerMalignant Solid Tumour
AstraZeneca700 enrolled307 locationsNCT07044336
Recruiting
Phase 3
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
AstraZeneca600 enrolled249 locationsNCT06989112
Recruiting
Phase 1Phase 2
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Breast CancerOvarian CancerEndometrial Cancer+1 more
AstraZeneca460 enrolled67 locationsNCT05123482
Recruiting
Phase 2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Gastric CancerOvarian CancerEndometrial Cancer+1 more
AstraZeneca454 enrolled95 locationsNCT05489211
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ovarian CancerEndometrial CancerProstate Cancer+5 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 1
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Breast CancerEndometrial CancerAdvanced Solid Tumor+2 more
Alterome Therapeutics, Inc.110 enrolled51 locationsNCT06533059
Recruiting
Phase 1Phase 2
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Ovarian CancerEndometrial CancerLung Adenocarcinoma
AstraZeneca506 enrolled60 locationsNCT05797168
Recruiting
Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
Endometrial Cancer
AstraZeneca50 enrolled1 locationNCT06995833
Recruiting
Phase 1
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Ovarian CancerEndometrial CancerAdvanced Solid Tumor+1 more
TORL Biotherapeutics, LLC90 enrolled14 locationsNCT05103683
Recruiting
Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+11 more
Daiichi Sankyo740 enrolled84 locationsNCT06172478
Recruiting
Phase 1Phase 2
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Endometrial CancerRecurrent Ovarian CancerRecurrent Fallopian Tube Cancer+2 more
Regeneron Pharmaceuticals890 enrolled51 locationsNCT03564340
Recruiting
Phase 1Phase 2
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Endometrial CancerAdvanced Solid TumorDiffuse Large B Cell Lymphoma+5 more
Novartis Pharmaceuticals275 enrolled60 locationsNCT04104776
Recruiting
Phase 2
Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)
Endometrial CancerEndometrial Neoplasms
Yonsei University30 enrolled1 locationNCT05795244
Recruiting
Phase 2
First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer
Endometrial CancerEndometrial CarcinomaRecurrent Endometrial Carcinoma+2 more
Yonsei University92 enrolled6 locationsNCT06502743
Recruiting
Not Applicable
Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer
Endometrial Cancer
Samsung Medical Center92 enrolled1 locationNCT05876130
Recruiting
Development and Management of Registry in Patients With Gynecologic Cancer in Korea
Ovarian CancerCervical CancerEndometrial Cancer+2 more
Asan Medical Center13,500 enrolled1 locationNCT05912972
Recruiting
Not Applicable
Randomized Comparison Between Sentinel Lymph Node Biopsy and Lymph Node Dissection in Early Stage Endometrial Cancer
Endometrial Cancer
Asan Medical Center810 enrolled1 locationNCT04845828